Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...
Sangamo (SGMO) stock faces challenges as Pfizer terminates partnership for hemophilia A gene therapy, impacting share price ...
Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...
The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...
Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.
Sangamo Therapeutics Inc. (SGMO) shares plunged in Tuesday's pre-market trading by over 50% after Pfizer Inc. (PFE) ...
Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...
Sangamo is on course to run out of money within months and has now lost access to up to $220 million in milestone payments ...
Sangamo, a gene therapy pioneer, loses a financial lifeline as Pfizer drops a gene therapy program for hemophilia.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a biotechnology company specializing in genomic medicine and gene therapies, stands at a critical juncture as it navigates a complex landscape of clinical ...